RM-493 ( DrugBank: - )

2 diseases

ID	Disease name (Link within this page)	Number of trials
193	Prader-Willi syndrome	1
202	Smith-Magenis syndrome	3

193. Prader-Willi syndrome

Clinical trials : 113 / Drugs : 111 - (DrugBank : 26) / Drug target genes : 48 - Drug target pathways : 102

diseases per page:

Showing 1 to 1 of 1 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02311673 (ClinicalTrials.gov)	February 2015	25/11/2014	Ph 2 Trial to Evaluate Safety & Efficacy of RM-493 in Obese Patients With Prader-Willi Syndrome	A Ph 2, Randomized, Double-Blind, Placebo-controlled Pilot Study to Assess the Effects of RM-493, a ...	Prader-Willi Syndrome	Drug: RM-493;Drug: Placebo	Rhythm Pharmaceuticals, Inc.	NULL	Completed	16 Years	65 Years	All	40	Phase 2	United States

First Previous1Next Last

202. Smith-Magenis syndrome

Clinical trials : 9 / Drugs : 10 - (DrugBank : 5) / Drug target genes : 4 - Drug target pathways : 7

diseases per page:

Showing 1 to 3 of 3 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2017-000387-14-GR (EUCTR)	10/01/2020	01/11/2019	Setmelanotide (RM-493) Phase 2 Treatment Trial in Patients with rare genetic disorders of obesity	Setmelanotide (RM-493) Phase 2 Treatment Trial in Patients with rare genetic disorders of obesity	- POMC/PCSK1/LEPR heterozygous- POMC/PCSK1/LEPR compound heterozygous or homozygous deficiency obesi ...	Product Name: setmelanotide Product Code: RM-493 INN or Proposed INN: setmelanotide Other descriptive n ...	Rhythm Pharmaceuticals, Inc.	NULL	Not Recruiting	Female: yes Male: yes	222	Phase 2	France;United States;Canada;Greece;Spain;Israel;Netherlands;Germany;United Kingdom
2	EUCTR2017-000387-14-GB (EUCTR)	24/05/2017	17/03/2017	Setmelanotide (RM-493) Phase 2 Treatment Trial in Patients with rare genetic disorders of obesity	Setmelanotide (RM-493) Phase 2 Treatment Trial in Patients with rare genetic disorders of obesity	- POMC/PCSK1/LEPR heterozygous- POMC/PCSK1/LEPR compound heterozygous or homozygous deficiency obesi ...	Product Name: setmelanotide Product Code: RM-493 INN or Proposed INN: setmelanotide Other descriptive n ...	Rhythm Pharmaceuticals, Inc.	NULL	Authorised-recruitment may be ongoing or finished	Female: yes Male: yes	150	Phase 2	United States;France;Greece;Canada;Spain;Israel;Netherlands;Germany;United Kingdom
3	EUCTR2017-000387-14-FR (EUCTR)		14/03/2019	Setmelanotide (RM-493) Phase 2 Treatment Trial in Patients with rare genetic disorders of obesity	Setmelanotide (RM-493) Phase 2 Treatment Trial in Patients with rare genetic disorders of obesity - ...	-LepR Deficiency Obesity -POMC Heterozygous Deficiency Obesity -POMC Epigenetic Deficiency Obesity - ...	Product Name: setmelanotide Product Code: RM-493 INN or Proposed INN: setmelanotide Other descriptive n ...	Rhythm Pharmaceuticals, Inc.	NULL	NA	Female: yes Male: yes	100	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - ( ...	United States;Portugal;Greece;Spain;Ireland;Turkey;Israel;United Kingdom;France;Canada;Australia;Ger ...

First Previous1Next Last